Celgene to allow sale of generic Revlimid before patent expiry

(Reuters) - Celgene Corp said it would allow the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States more than a year before the drug's patent expires.

http://ift.tt/1JsV9vE

from Reuters: Health News
via animenewspro